REG-Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
Globe Newswire•30/07/2026•01:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.